Brind.

Shield Therapeutics Receives FDA Approval for Oral Iron Therapy, Applies for AIM Listing

1 report, 1 independent Updated 07:30
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Shield Therapeutics plc received FDA approval for its oral iron therapy, ACCRUFeR®/FeRACCRU®. The company also submitted an application to the London Stock Exchange for admission to AIM trading, which is expected to become effective around November 25, 2026.

From investegate.co.uk

Why it matters

Some supportBrind's analysis of the reports

ACCRUFeR®/FeRACCRU® is noted as the first and only FDA-approved oral iron therapy to treat Iron Deficiency (ID)/Iron Deficiency Anemia (IDA). This therapy addresses a market opportunity in the United States valued at $2.3 billion.

From investegate.co.uk

Who's involved

  • FDAThe regulatory agency that granted approval for the oral iron therapy.
  • United States of AmericaThe jurisdiction where the drug is approved and addresses a $2.3 billion market opportunity.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped